ALTERITY THERAPEUTICS-ADR (ATHE) Stock Price, Forecast & Analysis
NASDAQ:ATHE • US02155X2053
ATHE Key Statistics, Chart & Performance
The current stock price of ATHE is 3.5093 USD. In the past month the price increased by 5.63%. In the past year, price decreased by -20.6%.
ATHE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ATHE. When comparing the yearly performance of all stocks, ATHE is a bad performer in the overall market: 80.37% of all stocks are doing better.
ATHE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATHE. While ATHE seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATHE Financial Highlights
Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 59.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.39% | ||
| ROE | -28.65% | ||
| Debt/Equity | 0 |
ATHE Forecast & Estimates
5 analysts have analysed ATHE and the average price target is 3.18 USD. This implies a price decrease of -9.42% is expected in the next year compared to the current price of 3.5093.
For the next year, analysts expect an EPS growth of -7376.5% and a revenue growth 1190.5% for ATHE
ATHE Ownership
ATHE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATHE
Company Profile
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Company Info
ALTERITY THERAPEUTICS-ADR
Level 14, 350 Collins Street
Melbourne VICTORIA VIC 3000 AU
CEO: David A. Stamler
Employees: 9
Phone: 61393494906
ALTERITY THERAPEUTICS-ADR / ATHE FAQ
What does ATHE do?
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
What is the stock price of ALTERITY THERAPEUTICS-ADR today?
The current stock price of ATHE is 3.5093 USD. The price decreased by -0.59% in the last trading session.
Does ATHE stock pay dividends?
ATHE does not pay a dividend.
What is the ChartMill rating of ALTERITY THERAPEUTICS-ADR stock?
ATHE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting ATHE stock to perform?
5 analysts have analysed ATHE and the average price target is 3.18 USD. This implies a price decrease of -9.42% is expected in the next year compared to the current price of 3.5093.
Should I buy ATHE stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATHE.
Can you provide the market cap for ALTERITY THERAPEUTICS-ADR?
ALTERITY THERAPEUTICS-ADR (ATHE) has a market capitalization of 63.61M USD. This makes ATHE a Micro Cap stock.